Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group
- PMID: 9558143
Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group
Erratum in
- Neurobiol Aging 1998 May-Jun;19(3):285
Abstract
The ideal biomarker for Alzheimer's disease (AD) should detect a fundamental feature of neuropathology and be validated in neuropathologically-confirmed cases; it should have a sensitivity >80% for detecting AD and a specificity of >80% for distinguishing other dementias; it should be reliable, reproducible, non-invasive, simple to perform, and inexpensive. Recommended steps to establish a biomarker include confirmation by at least two independent studies conducted by qualified investigators with the results published in peer-reviewed journals. Our review of current candidate markers indicates that for suspected early-onset familial AD, it is appropriate to search for mutations in the presenilin 1, presenilin 2, and amyloid precursor protein genes. Individuals with these mutations typically have increased levels of the amyloid Abeta42 peptide in plasma and decreased levels of APPs in cerebrospinal fluid. In late-onset and sporadic AD, these measures are not useful, but detecting an apolipoprotein E e4 allele can add confidence to the clinical diagnosis. Among the other proposed molecular and biochemical markers for sporadic AD, cerebrospinal fluid assays showing low levels of Abeta42 and high levels of tau come closest to fulfilling criteria for a useful biomarker.
Comment in
-
Consensus report of the Working Group on: molecular and biochemical markers of Alzheimer's disease.Neurobiol Aging. 1999 Mar-Apr;20(2):247. doi: 10.1016/s0197-4580(99)00083-4. Neurobiol Aging. 1999. PMID: 10537034 No abstract available.
Similar articles
-
[Search of biological markers of Alzheimer's disease].Ann Biol Clin (Paris). 2000 Sep-Oct;58(5):581-93. Ann Biol Clin (Paris). 2000. PMID: 11022101 Review. French.
-
Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele.Biol Psychiatry. 2004 Nov 1;56(9):670-6. doi: 10.1016/j.biopsych.2004.07.021. Biol Psychiatry. 2004. PMID: 15522251
-
Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.J Cell Physiol. 2006 Jul;208(1):39-46. doi: 10.1002/jcp.20602. J Cell Physiol. 2006. PMID: 16447254 Review.
-
MRI and CSF studies in the early diagnosis of Alzheimer's disease.J Intern Med. 2004 Sep;256(3):205-23. doi: 10.1111/j.1365-2796.2004.01381.x. J Intern Med. 2004. PMID: 15324364
-
[Advances in molecular biology and clinical study of amyloid precursor protein for Alzheimer's disease].Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004 Apr;26(2):201-9. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004. PMID: 15171563 Review. Chinese.
Cited by
-
Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia.J Neural Transm (Vienna). 2012 Jul;119(7):805-13. doi: 10.1007/s00702-012-0801-3. Epub 2012 Apr 19. J Neural Transm (Vienna). 2012. PMID: 22527776 Free PMC article.
-
Changes in intracranial venous blood flow and pulsatility in Alzheimer's disease: A 4D flow MRI study.J Cereb Blood Flow Metab. 2017 Jun;37(6):2149-2158. doi: 10.1177/0271678X16661340. Epub 2016 Jan 1. J Cereb Blood Flow Metab. 2017. PMID: 27492950 Free PMC article.
-
Use of biomarkers in clinical trials of Alzheimer disease: from concept to application.Mol Diagn Ther. 2011 Dec 1;15(6):313-25. doi: 10.1007/BF03256467. Mol Diagn Ther. 2011. PMID: 22188635
-
Prediction and longitudinal study of CSF biomarkers in mild cognitive impairment.Neurobiol Aging. 2009 May;30(5):682-90. doi: 10.1016/j.neurobiolaging.2007.08.010. Epub 2007 Sep 24. Neurobiol Aging. 2009. PMID: 17889968 Free PMC article.
-
Combined Analysis of CSF Tau, Aβ42, Aβ1-42% and Aβ1-40% in Alzheimer's Disease, Dementia with Lewy Bodies and Parkinson's Disease Dementia.Int J Alzheimers Dis. 2010 Aug 24;2010:761571. doi: 10.4061/2010/761571. Int J Alzheimers Dis. 2010. PMID: 20862375 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical